Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07514858

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, but still experience periods of time when their medication does not adequately control their motor symptoms. Some may also experience dyskinesia (other type of involuntary movements) as a side effect of their PD medications. The main goal of the trial is to learn whether adding Lu AF28996 to participants' optimized PD medications will help extending the time they spend with their movement symptoms being well-controlled and without bothersome dyskinesia.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Quest Research Institute - Alcanza - HyperCore - PPDS, Farmington Hills, Michigan, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • The participant was diagnosed with PD ≥3 years ago, with the diagnosis being established after the age of 30 years and consistent with the Movement Disorders Society (MDS) Clinical Diagnostic Criteria for "clinically established" or "clinically probable" PD.
  • The participant has a modified Hoehn and Yahr scale (mH&Y) stage ≤3 in the ON state and ≥2 and ≤4 in the OFF state.
  • The participant reports well recognizable, consistent motor fluctuations causing significant disability per investigator's judgement over a period of ≥3 months prior to screening.
  • The participants report motor fluctuations each day as measured by OFF-time during awake hours.

Key Exclusion Criteria:

  • The participant has previously been dosed with Lu AF28996.
  • The participant has participated in a clinical trial <30 days prior to screening.
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods.
  • The participant has taken any investigational medicinal product (IMP) <3 months or <5 half-lives, whichever is longer, prior to screening.
  • The participant has a Montréal Cognitive Assessment (MoCA) score ≤24 (adjusted for education).
  • The participant has an atypical, secondary, or drug-induced Parkinsonism (for example, metoclopramide, flunarizine), metabolic identified neurogenetic disorders (for example, Wilson's disease), encephalitis, or Parkinson Plus syndromes or other forms of atypical Parkinsonian syndromes (for example, progressive supranuclear palsy and multiple system atrophy).
  • The participant has severe, pervasive, disabling dyskinesia which, in the setting of the present trial, may interfere with his/her safe participation in the trial (for example, threat to falling, aspiration, etc.) as judged by the investigator.
  • The participant has unpredictable motor fluctuations as evidenced by an MDS-UPDRS Part IV Item 4.5 score ≥3 at screening and/or experiences wide, unpredictable fluctuations of PD symptoms per investigator's clinical judgement.

Note: Other protocol defined inclusion and exclusion criteria may apply

Treatment and study plan

Lu AF28996

Drug

Lu AF28996 will be administered orally per schedule specified in the arm description.

Placebo

Drug

Placebo matching to Lu AF28996 will be administered orally per schedule specified in the arm description.

Primary outcomes

  1. Change From Baseline to Week 19 in Daily Good ON Time Based on the Participant's Hauser Diary Entries

    Time frame: Baseline, Week 19

Secondary outcomes

  1. Change From Baseline to Week 19 in Daily OFF Time Based on Participant's Hauser Diary Entries

    Time frame: Baseline, Week 19

  2. Change From Baseline to Week 19 in Daily ON Time With Troublesome Dyskinesia Based on Participant's Hauser Diary Entries in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline

    Time frame: Baseline, Week 19

  3. Change From Baseline to Week 19 in Participant's Unified Dyskinesia Rating Scale (UDysRS) Total Score in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline

    Time frame: Baseline, Week 19

  4. Participant's Achievement at Week 19 of a Reduction in Daily OFF Time, Defined as >1.5 Hour/Day Reduction

    Time frame: Week 19

  5. Participant's Achievement at Week 19 of an Increase in Daily Good ON Time >1.5 Hour/Day

    Time frame: Week 19

  6. Participant's Achievement at Week 19 of a Reduction in Both Daily ON Time With Troublesome Dyskinesia AND in OFF time in Participants Reporting ≥1 Hour of Daily ON Time With Troublesome Dyskinesia at Baseline

    Time frame: Week 19

  7. Change From Baseline to Week 19 in Clinical Global Impression - Severity of Illness (CGI-S) Score

    Time frame: Baseline, Week 19

  8. Change From Baseline to Week 19 in Participant's Movement Disorder Society-Unified Parkinson's Disease-Rating Scale (MDS-UPDRS) Part III Score

    Time frame: Baseline, Week 19

  9. Change From Baseline to Week 19 in Participant's Movement Disorders Society Non-Motor Rating Scale (MDS-NMS) Domain Scores and Total Score

    Time frame: Baseline, Week 19

  10. Change From Baseline to Week 19 in Participant's Parkinson's Disease Sleep Scale Version 2 (PDSS-2) Total Score

    Time frame: Baseline, Week 19

  11. Change From Baseline to Week 19 in Participant's MDS-UPDRS Part IV (B) (Questions 4.1, 4.2, 4.3, 4.4 Item Scores), and Part IV Score

    Time frame: Baseline, Week 19

  12. Change From Baseline to Week 19 in Participant's MDS-UPDRS Total Score

    Time frame: Baseline, Week 19

  13. Change From Baseline to Week 19 in Participant's MDS-UPDRS Part I Score

    Time frame: Baseline, Week 19

  14. Change From Baseline to Week 19 in Participant's MDS-UPDRS Part II Score

    Time frame: Baseline, Week 19

  15. Change From Baseline to Week 19 in Participant's Parkinson's Disease Questionnaire-39 (PDQ-39) Score

    Time frame: Baseline, Week 19

  16. Change From Baseline to Week 19 in Participant's EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale Score

    Time frame: Baseline, Week 19

  17. Change From Baseline to Week 19 in Daily Oral Levodopa (mg)

    Time frame: Baseline, Week 19

  18. Change From Baseline to Week 19 in Levodopa-equivalent Dose (LED)

    Time frame: Baseline, Week 19

  19. Change From Baseline to Week 19 in Total Levodopa-equivalent Daily Dose (LEDD)

    Time frame: Baseline, Week 19

  20. Patient Global Impression of Change (PGI-C) Score at Week 19

    Time frame: Week 19

  21. Plasma Concentrations of Lu AF28996 and Metabolites

    Time frame: Weeks 7 and 15

  22. Change From Baseline to Week 19 in Daily ON Time With Troublesome Dyskinesia Based on Participant's Hauser Daily Entries

    Time frame: Baseline, Week 19

  23. Change From Baseline to Week 19 in Daily ON Time Without Troublesome Dyskinesia Based on Participant's Hauser Daily Entries

    Time frame: Baseline, Week 19

  24. Change From Baseline to Week 19 in Daily ON Time With Non-troublesome Dyskinesia Based on Participant's Hauser Daily Entries

    Time frame: Baseline, Week 19

  25. Change From Baseline to Week 19 in Participant's UDysRS Total Score and Combined Partial Scores of Part 1 + Part 2, Part 3 + Part 4, and Part 1 + Part 3 + Part 4, in Participants With UDysRS Total Score ≥20 at Baseline

    Time frame: Baseline, Week 19

  26. Number of Participants With Achievement of a Reduction in Daily ON Time With Troublesome Dyskinesia at Week 19

    Time frame: Week 19

  27. Number of Participants With Achievement of No Worsening in Daily ON Time With Troublesome Dyskinesia at Week 19

    Time frame: Week 19

Study contacts

Contact information is provided by the study sponsor or research team.

Email contact via H. Lundbeck A/S

CONTACT

[email protected]

+45 36301311

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Registry information

Official study title

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Trial of Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations

Acronym: DARE2

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Apr 7, 2026
Registry last updated
Sep 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.